Non-Current Liabilities
Total Liabilities
Vertex Pharmaceuticals Total Liabilities increased by 2.1% to $7.12B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.6%, from $6.38B to $7.12B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows an upward trend with a 17.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
How to read this metric
A rising total liability balance relative to equity indicates higher financial leverage and potentially increased risk.
Detailed definition
This is the sum of all current and non-current liabilities, representing the total financial obligations of the company...
Peer comparison
Standard metric for assessing corporate solvency and capital structure across all industries.
Metric ID:
total_liabilitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.03B | $3.09B | $3.33B | $3.35B | $3.65B | $3.68B | $4.24B | $4.54B | $4.88B | $5.21B | $5.15B | $5.37B | $5.36B | $6.61B | $6.12B | $6.38B | $6.86B | $7.54B | $6.98B | $7.12B |
| QoQ Change | — | +2.1% | +7.9% | +0.5% | +8.9% | +0.8% | +15.3% | +7.2% | +7.4% | +6.9% | -1.2% | +4.3% | -0.2% | +23.4% | -7.3% | +4.3% | +7.5% | +9.9% | -7.5% | +2.1% |
| YoY Change | — | — | — | — | +20.6% | +19.1% | +27.2% | +35.6% | +33.7% | +41.8% | +21.5% | +18.3% | +9.8% | +26.8% | +18.9% | +18.9% | +28.1% | +14.1% | +13.9% | +11.6% |
Range$3.03B – $7.54B
CAGR+19.8%
Avg YoY Growth+22.5%
Median YoY Growth+19.8%
Total Liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's total liabilities?
- Vertex Pharmaceuticals (VRTX) reported total liabilities of $7.12B in Q1 2026.
- How has Vertex Pharmaceuticals's total liabilities changed year-over-year?
- Vertex Pharmaceuticals's total liabilities increased by 11.6% year-over-year, from $6.38B to $7.12B.
- What is the long-term trend for Vertex Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's total liabilities has grown at a 17.9% compound annual growth rate (CAGR), from $3.07B to $6.98B.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and stakeholders.